Harbin Gloria Pharmaceuticals Co., Ltd
002437.SZ
Get informed when a big investor buys or sells
+ FollowMarket Cap$8.23B
Close$
$2.90
15.5% downside
Current Fair Value
15.5% downsideOvervalued by 15.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $8.23 Billion |
|---|---|
| Enterprise Value | $7.82 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.17 |
| Beta | 0.09 |
| Outstanding Shares | 2,209,792,726 |
Return
| Return on Equity | 16.25% |
|---|---|
| Return on Assets | 12.31% |
| Return on Invested Capital | 18.19% |
Valuation & Multiples
| P/E Ratio | 20.27 |
|---|---|
| PEG | -148.73 |
| Price to Sales | - |
| Price to Book Ratio | 3.43 |
| Enterprise Value to Revenue | 3.83 |
| Enterprise Value to EBIT | 17.08 |
| Enterprise Value to Net Income | 19 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Insider Trades
Next Earnings Call
Expected Date
October 28, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Harbin Gloria Pharmaceuticals Co., Ltd
2,350 employees
CEO: Leifeng Guo Harbin Gloria Pharmaceuticals Co., Ltd. is a Chinese pharmaceutical enterprise primarily focused on the research, development, manufacturing, and commercialization of various medicinal products within the People's Republic of China. The ...